research <p>Optimal Management of Frontal Fibrosing Alopecia: A Practical Guide</p>
Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.
Search
for
Sort by
Research
240-270 / 1000+ results 
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men
Dutasteride helps reduce heavy drinking, especially for those who drink to cope.
research Platelet‐rich plasma with low dose oral minoxidil (1.25mg versus 2.5mg) along with trichoscopic pre‐ and post‐treatment evaluation
Combining platelet-rich plasma therapy with low dose oral minoxidil improved hair growth in men with hair loss, with slightly higher satisfaction at the higher minoxidil dose.
research Androgenetic alopecia. Diagnostic and therapeutic recommendations of the Polish Dermatological Society
Use trichoscopy to diagnose hair loss; treat with minoxidil, finasteride, or dutasteride; consider platelet-rich plasma and spironolactone.
research Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
research Androgens and Parkinson’s disease: the role in humans and in experiment
Dutasteride shows promise as a potential treatment for Parkinson's disease.
research Overactive bladder in men
Finasteride increases hair count and improves hair growth with low risk of side effects.
research Encapsulación en ciclodextrinas de compuestos con actividad frente a la alopecia androgénica masculina.
Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
Low-dose dutasteride effectively and safely promotes hair growth in men.
research Farmácia Serpa Pinto, Porto e Serviços Farmacêuticos do Instituto Português Oncologia do Porto Francisco Gentil, EPE, Porto
Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
research Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study
Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.
research 5α- Reductase Inhibitors in Prostate Cancer: An Overview
5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
research Cosmetic Approach for Men
Men are increasingly seeking quick-result cosmetic treatments for their thicker, oilier skin and hair loss issues.
research The switch from patented medicine to the generic one: an option or a necessity?
Switching to generic drugs is necessary but faces communication and information challenges.
research COVID-19: The question of genetic diversity and therapeutic intervention approaches
COVID-19 treatments and vaccines face challenges due to genetic differences in people and the virus.
research Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
Food intake, not genetics, affects how the body processes tadalafil and finasteride.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Hormonal and Genetic Etiology of Male Androgenetic Alopecia
research Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients
Finasteride may cause lasting sexual and mental health issues, and genetic screening could help prevent them.
research Congenital Zinc Deficiency from Mutations of theSLC39A4Gene as the Genetic Background of Acrodermatitis Enteropathica
A Korean boy's skin and digestive symptoms were caused by a rare genetic disorder that affects zinc absorption, and he got better with zinc supplements.
research Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.
research A bibliometric analysis of alternative drug therapy options in the treatment of androgenetic alopecia
Dutasteride is the most studied alternative drug for androgenetic alopecia, but more high-quality research is needed.
research Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
research Selection signatures for fiber production in commercial species: A review
Genomic research can help improve the quality and production of natural fibers in animals.
research Androgenetic alopecia: An update
Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
research Mesotherapy vs PRP: Hair loss
PRP generally shows better results for hair regrowth than mesotherapy, but more research is needed.
research Update Treatment of Male Androgenetic Alopecia
The best treatment for male pattern baldness is a combination of topical minoxidil and oral finasteride.
research Combined C3b and Factor B Autoantibodies and MPGN Type II
The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.